Next 10 |
home / stock / cadl / cadl articles
Candel Therapeutics, Inc. (NASDAQ: CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immun...
Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEa...
Shares of Ross Stores, Inc. (NASDAQ:ROST) rose sharply in today's pre-market trading after the company reported better-than-expected earnings ...
NEEDHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceut...
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday. Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wedn...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...
Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for ...
Friday, Candel Therapeutics Inc (NASDAQ:CADL) shares are trading higher on heavy volume with a session volume of 7.89 million versus the ...
The U.S. stock market experienced a downturn on Thursday, with the Dow Jones index falling by 1.35% to 38,596.98. The NASDAQ and the S&P 500 al...
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approved CAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poste...
2024-05-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Candel Therapeutics, Inc. (NASDAQ: CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immun...